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Abstract Adenylate cyclase activity in NS20Y cells expressing
D2L dopamine receptors was examined following chronic
treatment with norepinephrine and epinephrine. Initial acute
experiments revealed that both norepinephrine and epinephrine
inhibited forskolin-stimulated cyclic AMP accumulation via D2
receptors. Furthermore, chronic (18 h) activation of D2 dopamine
receptors by norepinephrine or epinephrine induced a marked
increase (s 10-fold) in subsequent forskolin-stimulated cyclic
AMP accumulation. This heterologous sensitization of adenylate
cyclase activity was blocked by D2 dopamine receptor antago-
nists and by pertussis toxin pretreatment. In contrast, concurrent
activation of GKs or adenylate cyclase did not appear to alter
noradrenergic agonist-induced sensitization. ß 2001 Published
by Elsevier Science B.V. on behalf of the Federation of Euro-
pean Biochemical Societies.
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1. Introduction
Dopaminergic systems have been implicated in the pathol-
ogy and pharmacotherapy of many central nervous system
disorders. Furthermore, evidence suggests that the norad-
renergic system may also modulate dopamine signaling. For
example, noradrenergic neurons project to several brain re-
gions that contain both norepinephrine uptake sites and D2-
like dopamine receptors, including the ventral tegmental area,
amygdala, and cortex [1^4]. Furthermore, in vitro studies have
provided direct evidence that norepinephrine is an agonist at
D2-like dopamine receptors [5^8]. Norepinephrine stimulates
D2 dopamine receptor-mediated inhibition of cyclic AMP ac-
cumulation and high a⁄nity GTPase activity in rat striatal
membranes [5,8]. Studies examining recombinant dopamine
receptors in heterologous expression systems report that nor-
epinephrine has agonist activity at both D2 and D4 dopamine
receptors [6,8].
The acute activation of D2-like dopamine receptors is
linked to inhibition of adenylate cyclase (EC 4.6.1.1) activity,
however, several studies have shown that both sub-acute (2 h)
and chronic (18 h) activation of D2 and D4 receptors induces
heterologous sensitization (supersensitization) of adenylate cy-
clase activity [9^15]. Heterologous sensitization is character-
ized by enhanced drug-stimulated cyclic AMP accumulation
in cells that were previously exposed to D2 dopamine receptor
agonists. Short-term (2 h) D2 dopamine receptor-mediated
sensitization of adenylate cyclase is prevented by coincubation
with D2 dopamine receptor antagonists and by pertussis toxin
treatment [13,16], however, the exact molecular mechanisms
of heterologous sensitization remain unknown.
Because D2 dopamine receptor-induced heterologous sensi-
tization leads to an upregulation of the cyclic AMP system,
such drug-induced neuroadaptations may be associated with
neuropsychiatric disorders that may involve dopamine and
norepinephrine signaling [17^19]. The present study was de-
signed to examine the ability of norepinephrine and epine-
phrine to induce heterologous sensitization in NS20Y neuro-
blastoma cells expressing the long (444-amino acid) form of
D2 dopamine receptor (D2L). We now report that chronic
treatment of NS20Y neuroblastoma cells expressing the D2L
dopamine receptor (NS20Y-D2L) with norepinephrine or epi-
nephrine markedly enhanced subsequent forskolin-stimulated
cyclic AMP accumulation. This long-term heterologous sensi-
tization did not occur in wild-type NS20Y cells and was
blocked by D2 dopamine receptor antagonists or by pertussis
toxin pretreatment. Furthermore, the e¡ects of persistent ag-
onist activation of D2 dopamine receptors were not altered by
co-activation of the endogenous GKs-coupled L adrenergic
receptor or by direct activation of adenylate cyclase.
2. Materials and methods
2.1. Materials
[3H]Cyclic AMP (25 Ci/mmol) was purchased from NEN Life Sci-
ence Products (Boston, MA, USA) and [3H]spiperone (104 Ci/mmol)
from Amersham Life Sciences (Arlington Heights, IL, USA). Quin-
pirole, epinephrine, norepinephrine, (+)-butaclamol, propranolol, spi-
perone, and forskolin were purchased from Research Biochemicals
International (Natick, MA, USA). Dopamine (3-hydroxytyramine),
isoproterenol, pertussis toxin, growth media and most other reagents
were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
2.2. Production and maintenance of cell lines
Transfection of NS20Y cells with the D2L vector was carried out by
calcium phosphate precipitation as described previously [13]. Brie£y,
pcDNA1-D2L (20 Wg) and pBabe Puro (2 Wg) were mixed with 0.5 ml
of 0.25 M CaCl2 and 0.5 ml of 2UBBS (50 mM N,N-bis-(2-hydroxy-
ethyl)-2-aminoethanesulfonic acid, 280 mM NaCl, 1.5 mM NaHPO4)
was added. The mixture was incubated for 25 min and added drop-
wise to exponentially growing NS20Y cells in a 10-cm tissue culture
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plate. Transfectants were isolated and screened by [3H]spiperone bind-
ing. NS20Y-D2L cells were maintained in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) supplemented with 5% fetal bovine serum (FBS)
and 5% calf bovine serum (CBS), penicillin/streptomycin, and puro-
mycin (2 Wg/ml). Cells were grown in a humidi¢ed incubator at 37‡C
in the presence of 10% CO2.
2.3. Cyclic AMP accumulation assays
For sensitization assays, con£uent cells in 48-well tissue culture
clusters were preincubated for 18 h in DMEM assay bu¡er
(DMEM supplemented with 5% FBS and 5% CBS in the presence
of drugs at 37‡C in a humidi¢ed incubator with 10% CO2). For
pertussis toxin treatment experiments, cells were initially treated
with pertussis toxin (300 ng/well) in a volume of 200 Wl for 2 h. After
this 2-h incubation, 200 Wl of a 20-WM agonist solution (¢nal agonist
concentration, 10 WM) was added to the wells which already con-
tained pertussis toxin (the ¢nal concentration of pertussis toxin was
150 ng/ml in a total of 400 Wl) and the cells were incubated for an
additional 18 h. Following all 18-h drug treatments, the cells were
washed three times for 3^4 min each with 200 Wl EBSS assay bu¡er
(Earle’s balanced salt solution, containing 15 mM 4-(2-hydroxyethyl)-
1-piperazine-ethanesulfonic acid (HEPES), 2% CBS and 0.02% ascor-
bic acid). To quantify sensitization of adenylate cyclase, forskolin (10
WM) was added in the presence of 1 WM spiperone to preclude acute
e¡ects of D2-like dopamine receptor activation by residual agonist
[13]. For acute experiments, cells were preincubated with 200 Wl
EBSS assay bu¡er for 10 min and placed on ice. Agonists in the
absence or presence of antagonists were added to wells prior to the
addition of forskolin (10 WM). Incubations were carried out for 15
min at 37‡C and the assay bu¡er was decanted. The culture plates
were placed on ice and lysed with 3% trichloroacetic acid (100 Wl). The
48-well plates were stored at 4‡C for at least 1 h before quanti¢cation
of cyclic AMP.
2.4. Quanti¢cation of cyclic AMP
Cyclic AMP was quanti¢ed using a competitive binding assay [20],
with minor modi¢cations [16]. Duplicate samples of the 3% trichloro-
acetic acid cell lysates (2^10 Wl) were added to reaction tubes each
containing cyclic AMP assay bu¡er (100 mM Tris^HCl, pH 7.4, 100
mM NaCl, 5 mM EDTA). [3H]Cyclic AMP (1 nM ¢nal concentra-
tion) was added to each assay, followed by cyclic AMP-binding pro-
tein (V100 Wg of crude adrenal extract in 500 Wl of cyclic AMP
bu¡er). The reaction tubes were incubated on ice for 2 h, and the
samples were then harvested by ¢ltration (Whatman GF/C ¢lters)
using a 96-well Packard Filtermate cell harvester. Filters were allowed
to dry, and 40 Wl of Micoscint 0 scintillation £uid was added to each
sample well. Radioactivity on the ¢lters was determined using a Pack-
ard TopCount scintillation counter. Cyclic AMP concentrations in
each sample were estimated in duplicate from a standard curve rang-
ing from 0.1 to 100 pmol cyclic AMP/assay. Dose^response curves for
cyclic AMP accumulation were analyzed by non-linear regression us-
ing the program GraphPad Prism (San Diego, CA, USA). All values
for cyclic AMP accumulation are expressed as pmol cyclic AMP per
well.
3. Results
3.1. Acute regulation of cyclic AMP accumulation in
NS20Y-D2L cells
We examined the ability of selected drugs to acutely mod-
ulate cyclic AMP accumulation in NS20Y-D2L cells. The D2
dopamine receptor agonist, quinpirole, inhibited forskolin-
stimulated cyclic AMP accumulation, and the inhibition was
blocked completely by the D2 dopamine antagonist, spiperone
(Fig. 1a). In contrast, propranolol did not alter the maximal
quinpirole response in NS20Y-D2L cells (Fig. 1a). Similarly,
the natural ligand dopamine (10 WM) inhibited forskolin-
stimulated cyclic AMP accumulation by 94 þ 2% (n = 3) and
93 þ 2% (n = 3) in the absence and presence of propranolol,
respectively. We then examined the ability of epinephrine and
norepinephrine to modulate cyclic AMP accumulation in
NS20Y-D2L cells. In the absence of forskolin, the addition
of norepinephrine and epinephrine produced no signi¢cant
e¡ect on cyclic AMP accumulation (data not shown). In con-
trast, when norepinephrine or epinephrine was added in the
presence of forskolin, each drug produced a signi¢cant in-
crease in cyclic AMP accumulation when compared to forsko-
Fig. 1. Acute modulation of forskolin-stimulated cyclic AMP accu-
mulation in NS20Y-D2L cells. Cyclic AMP accumulation in NS20Y-
D2L cells was stimulated with 10 WM forskolin in the absence or
presence of the indicated agonist (10 WM). a = quinpirole, b = norepi-
nephrine, and c = epinephrine. Where indicated, some experiments
were completed in the presence of 1 WM propranolol or 1 WM spi-
perone. Cyclic AMP accumulation assays were carried out for 15
min at 37‡C and reactions were terminated as described in Section
2. Data shown are the mean þ standard error of ¢ve to eight inde-
pendent experiments, each assayed in duplicate. *P6 0.05 compared
to vehicle exposed cells (Student’s t-test).
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lin alone (Fig. 1b,c). The addition of the L adrenergic antag-
onist propranolol prevented this increase and revealed that
both norepinephrine and epinephrine had signi¢cant intrinsic
activity for inhibiting forskolin-stimulated cyclic AMP accu-
mulation. Speci¢cally, in the presence of propranolol, norepi-
nephrine and epinephrine inhibited forskolin-stimulated cyclic
AMP accumulation by 76 þ 7% (n = 5) and 77 þ 6% (n = 6),
respectively (Fig. 1b,c). In experiments that examined the ef-
fects of the D2 dopamine antagonist spiperone on drug-modu-
lated cyclic AMP accumulation, spiperone tended to potenti-
ate both norepinephrine- and epinephrine-stimulated cyclic
AMP accumulation (Fig. 1b,c).
3.2. Sensitization of forskolin-stimulated cyclic AMP
accumulation in NS20Y-D2L cells
Long-term (18 h) pretreatment of NS20Y-D2L cells with 10
WM norepinephrine, 10 WM epinephrine, or 10 WM quinpirole
resulted in marked sensitization of forskolin-stimulated cyclic
AMP accumulation (Fig. 2a). In contrast, pretreatment with
dopamine (10 WM) alone did not produce sensitization, pre-
sumably due to degradation under the culture conditions used
(see [12]). The EC50 values for heterologous sensitization by
norepinephrine and epinephrine were 2.3 þ 0.3 WM (n = 3) and
2.1 þ 0.7 WM (n = 3), respectively. An experiment with the syn-
thetic D2 agonist quinpirole revealed an EC50 value of 0.02
WM (n = 1) which is similar to a value reported in our previous
study of short-term heterologous sensitization in NS20Y-D2L
cells [16]. Similar treatments of wild-type (untransfected)
NS20Y neuroblastoma cells did not alter subsequent forsko-
lin-stimulated cyclic AMP accumulation. Speci¢cally, cyclic
AMP accumulation values expressed as a percentage of ve-
hicle-treated cell values were 100 þ 2% (n = 7), 105 þ 11%
(n = 7), and 108 þ 7% (n = 7) in quinpirole-, epinephrine-, and
norepinephrine-treated cells, respectively. We then examined
D2 dopamine receptor speci¢city and found that the e¡ects of
quinpirole, norepinephrine, or epinephrine treatment on sub-
sequent forskolin-stimulated cyclic AMP accumulation in
NS20Y-D2L cells were blocked by the D2 dopamine receptor
antagonist, spiperone (Fig. 2b^d).
We next investigated the role of G protein-regulated path-
ways in drug-induced sensitization of adenylate cyclase. Pre-
treatment with pertussis toxin completely blocked long-term
heterologous sensitization of forskolin-stimulated cyclic AMP
accumulation mediated by quinpirole, and also prevented nor-
Fig. 2. Long-term agonist-induced heterologous sensitization of forskolin-stimulated cyclic AMP accumulation. a: NS20Y-D2L cells were treated
with vehicle or the indicated agonist (10 WM) for 18 h at 37‡C and the response to forskolin (10 WM for 15 min) was then measured. b^d: Ag-
onist (10 WM) pretreatments (18 h) were completed in the absence (Control) or presence of 1 WM spiperone (+Spip), 1 WM propranolol
(+Prop), 10 WM forskolin (+FSK), or following treatment with pertussis toxin (+PTX). For pertussis toxin treatment, cells were initially treated
with pertussis toxin (300 ng/well) for 2 h, followed by an 18-h incubation with agonist in the presence of pertussis toxin (150 ng/ml). Following
all drug treatments, cells were washed extensively with EBSS, and cyclic AMP accumulation was stimulated with forskolin (10 WM) for 15 min.
Data in b^d are expressed as the percentage of forskolin-stimulated cyclic AMP accumulation in cells treated with agonist alone (control).
Data shown are the mean þ standard error of three to nine independent experiments, each assayed in duplicate. *P6 0.001 compared to ve-
hicle-treated (a) or control (b^d) cells (Dunnett’s post hoc ANOVA).
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epinephrine- and epinephrine-induced sensitization of forsko-
lin-stimulated cyclic AMP accumulation (Fig. 2b^d). We then
compared drug-induced sensitization in the absence and pres-
ence of the L adrenergic receptor antagonist, propranolol, to
examine the potential role of GKs-stimulated cyclic AMP ac-
cumulation on GKi=o-induced heterologous sensitization. The
results of our studies demonstrate that antagonism of L ad-
renergic receptor activation did not alter heterologous sensi-
tization induced by norepinephrine and epinephrine (Fig.
2c,d). Similarly, propranolol did not alter quinpirole-mediated
sensitization (Fig. 2b). Additional studies revealed that direct
activation of adenylate cyclase by 10 WM forskolin during
agonist pretreatment does not alter heterologous sensitization
(Fig. 2b^d).
4. Discussion
The experiments described above demonstrate that norepi-
nephrine and epinephrine are agonists at recombinant D2
dopamine receptors. Our results are in agreement with studies
describing the ability of norepinephrine to activate D2 dopa-
mine receptors for inhibition of cyclic AMP accumulation [5]
and to stimulate GTPase activity [8] in rat striatal membranes.
These inhibitory e¡ects of norepinephrine or epinephrine were
readily observed in the presence of propranolol, indicating
that the acute action of each drug on L adrenergic receptors
is quite robust in the presence of forskolin. This observation is
consistent with the synergistic action of forskolin and GKs on
adenylate cyclase activity following L adrenergic receptor ac-
tivation [21].
In the present study we observed that long-term activation
of D2 dopamine receptors by quinpirole, norepinephrine, or
epinephrine resulted in heterologous sensitization of forskolin-
stimulated cyclic AMP accumulation. This heterologous sen-
sitization was prevented when agonist pretreatments were
combined with the D2 antagonist spiperone. In agreement
with short-term heterologous sensitization studies examining
D2-like receptors [12,13,16], we found that pretreatment with
pertussis toxin completely blocked long-term heterologous
sensitization of forskolin-stimulated cyclic AMP accumula-
tion. Our results are also consistent with the report that per-
tussis toxin treatment blocks long-term sensitization of mem-
brane adenylate cyclase activity by D2 dopamine receptor
agonists in Ltk-D2S cells [9]. In addition, the present results
implicate the activation of GKi=o proteins (via D2 receptors) in
sensitization following chronic treatment with the adrenergic
agonists, norepinephrine and epinephrine.
We also examined the e¡ects of concurrent stimulation of
adenylate cyclase during long-term heterologous sensitization.
Our studies revealed that norepinephrine- and epinephrine-
induced heterologous sensitization was not altered in the pres-
ence of propranolol (see Fig. 2c,d) suggesting that activation
of the L adrenergic receptor-GKs-adenylate cyclase signaling
pathway does not alter long-term heterologous sensitization.
Furthermore, it was also demonstrated that heterologous sen-
sitization is not a¡ected by direct activation of adenylate cy-
clase using forskolin (Fig. 2b^d). Together, these observations
suggest that activation of the protein kinase A pathway does
not alter D2 dopamine receptor-induced supersensitization of
adenylate cyclase in NS20Y-D2L cells. This result contrasts
with an earlier study in Ltk-D2S cell membranes demonstrat-
ing that activators of protein kinase A may enhance long-term
D2 agonist-mediated sensitization [9]. We have previously
shown, however, that direct activation of protein kinase A
or activation of the adenylate cyclase pathway via GKs-
coupled receptors does not alter short-term D2 dopamine re-
ceptor-mediated sensitization of adenylate cyclase activity in
intact cells [13]. More recently, we have reported that direct
activation of adenylate cyclase with forskolin does not alter
short- or long-term heterologous sensitization by D4 dopa-
mine receptors in human embryonic kidney (HEK293) cells
[12].
We chose NS20Y cells for the current studies of D2 dopa-
mine receptor function because they are of neuronal origin
and have many features characteristic of striatal cholinergic
cells [22]. We have previously characterized the D2 dopamine
receptor pharmacology in NS20Y-D2L cells [16], and in the
present study we examined the ability of norepinephrine and
epinephrine to modulate D2 dopamine receptor activity. Nor-
epinephrine and epinephrine were agonists in experiments ex-
amining the e¡ects of both acute and chronic activation of D2
dopamine receptors in NS20Y-D2L cells. Moreover, chronic
activation of D2 dopamine receptors by norepinephrine or
epinephrine resulted in a marked degree of heterologous sen-
sitization of adenylate cyclase that was similar to the heterol-
ogous sensitization produced by the D2-selective agonist,
quinpirole (Fig. 2a). Further, norepinephrine and epinephrine
are also agonists at the dopamine D4 receptor [6,7], which is
expressed in brain areas that receive noradrenergic innerva-
tion [23]. Together, these observations suggest that crosstalk
among noradrenergic neurons and neurons expressing D2-like
dopamine receptors may be important for interpretation of in
vivo biochemical and behavioral studies.
The observation that norepinephrine is an agonist at D2-
like receptors may be important in psychiatric disorders that
involve dopamine and norepinephrine function such as schizo-
phrenia, depression, and drug abuse. Interactions between
norepinephrine and dopamine at catecholamine transporters
have been described [4,24], and the heterologous sensitization
data presented herein suggest an additional level of interaction
between dopamine and norepinephrine systems. Furthermore,
a norepinephrine transporter-de¢cient mouse model was re-
cently shown to have increased sensitivity to psychostimulants
and D2-like receptor agonists [25]. Together these observa-
tions provide evidence that norepinephrine and drugs that
modulate synaptic levels of norepinephrine are important reg-
ulators of dopamine receptor signaling.
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